THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience

by Richard P. Baum, Harshad R. Kulkarni
Published 2012-01-01

8-Year Survival with a Metastatic Thymic Neuroendocrine Tumor: Emphasis on Redefining “Treatment Objectives” Using “Personalized” Peptide Receptor Radionuclide Therapy with 177LU-...

by Ameya D. Puranik, MD, FEBNM, Harshad R. Kulkarni, MD, Aviral Singh, MD, Richard P. Baum, MD, PhD
Published 2015-01-01

Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides.

by Peter Kletting, Christiane Schuchardt, Harshad R Kulkarni, Mostafa Shahinfar, Aviral Singh, Gerhard Glatting, Richard P Baum, Ambros J Beer
Published 2016-01-01

Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer

by Cristina Müller, Aviral Singh, Christoph A. Umbricht, Harshad R. Kulkarni, Karl Johnston, Martina Benešová, Stefan Senftleben, Dirk Müller, Christiaan Vermeulen, Roger Schibli, Ulli Köster, Nicholas P. van der Meulen, Richard P. Baum
Published 2019-07-01